DNDN Options Trading Dendreon FDA has approved PROVENGE Stock Trading Video - 1 views
-
Brian Plain on 30 Apr 10Dendreon Provenge Approval Call Summary (45.50 +5.88) -Update : During the call, the co said that it will provide Provenge to 2000 patients in next 12 months. Co said that demand for Provenge will exceed co's ability to provide it in the first 12 months; will continue build out of manufacturing capabilities. Mgmt said that 1 infusion will cost $31k; complete course will cost $93k. and EPS of $1.65.